Search results
AbbVie (NYSE:ABBV) Shares Down 0.1%
ETF DAILY NEWS· 9 hours agoAbbVie Inc. (NYSE:ABBV – Get Free Report)’s stock price dropped 0.1% during mid-day trading on Thursday . The stock traded as low as $157.76 and last traded at $159.38. Approximately ...
US pharma giant Cencora says Americans' health information stolen in data breach
TechCrunch· 1 day agoU.S. pharmaceutical giant Cencora says it is notifying affected individuals that their personal and...
AbbVie (NYSE:ABBV) vs. Cosmo Pharmaceuticals (OTC:CMOPF) Head to Head Review
ETF DAILY NEWS· 16 hours agoAbbVie (NYSE:ABBV – Get Free Report) and Cosmo Pharmaceuticals (OTC:CMOPF – Get Free Report) are both medical companies, but which is the better investment? We will compare ...
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever | The Motley Fool
The Motley Fool· 9 hours agoThe key is to generate passive income. AbbVie (ABBV -0.76%) is one of the world's biggest...
Why AbbVie (ABBV) is a Top Value Stock for the Long-Term
Zacks via Yahoo Finance· 2 days agoWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the...
1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165? | The Motley...
The Motley Fool· 5 days agoWall Street is feeling pretty good about AbbVie's (ABBV -1.19%) performance in 2024 so far. Chen...
2 Billion More Reasons to Buy AbbVie Stock
Motley Fool via Yahoo Finance· 3 days agoThere are plenty of reasons to buy a leading biopharma business like AbbVie (NYSE: ABBV), and investors just got at least a few more. Thanks to a large...
This Is What Whales Are Betting On AbbVie - AbbVie (NYSE:ABBV)
Benzinga· 3 days agoLoading... Loading... Investors with a lot of money to spend have taken a bullish stance on AbbVie ABBV . And retail traders should know. We noticed this today when the positions ...
Kristin Chenoweth Says 'It's Wonderful to Find Your Person' After Marrying Josh Bryant: 'I Waited...
OK! Magazine· 4 days agoShe finally got that ring!
AbbVie Completes Acquisition of Landos Biopharma
Morningstar· 2 days agoWith the completion of the acquisition, Landos is now part of AbbVie. Landos' lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like ...